Pekin Singer Strauss Asset Management IL Decreases Holdings in Becton, Dickinson and Company (BDX)

Pekin Singer Strauss Asset Management IL lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 0.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,017 shares of the medical instruments supplier’s stock after selling 7 shares during the period. Pekin Singer Strauss Asset Management IL’s holdings in Becton, Dickinson and were worth $394,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Bessemer Group Inc. lifted its holdings in Becton, Dickinson and by 1.4% in the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock valued at $190,827,000 after purchasing an additional 13,263 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Becton, Dickinson and by 5.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock valued at $6,438,000 after purchasing an additional 1,819 shares in the last quarter. Boston Financial Mangement LLC lifted its holdings in Becton, Dickinson and by 10.2% in the 1st quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock valued at $10,218,000 after purchasing an additional 5,152 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Becton, Dickinson and by 1.2% in the 1st quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after purchasing an additional 39,362 shares in the last quarter. Finally, AMG National Trust Bank lifted its holdings in Becton, Dickinson and by 4.2% in the 1st quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after purchasing an additional 401 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

Becton, Dickinson and Company (BDX) opened at 202.20 on Wednesday. The stock has a market cap of $46.01 billion, a price-to-earnings ratio of 58.56 and a beta of 1.06. The stock’s 50 day moving average price is $200.08 and its 200 day moving average price is $191.02. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.35 earnings per share. Analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.44%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thestockobserver.com/2017/09/13/pekin-singer-strauss-asset-management-il-decreases-holdings-in-becton-dickinson-and-company-bdx.html.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

BDX has been the topic of a number of research reports. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation restated a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, July 17th. BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Finally, Cowen and Company restated an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $196.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply